Dr John Marshall on recent publications, both positive and negative, that may change your practice.

Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.

Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.

Dr Mark Kris on the big take-away lessons from the recent New York Lung Cancers Symposium.

Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes.

Dr David Kerr describes an epidemiologic study that found three standout risk factors for cancer in Chinese men and women.

Even a brief conversation about exercise can reap significant health benefits to patients, argues Dr Markman.

The sign of a mature oncologist is knowing when not to treat someone, says Dr Kerr. A new tool may bolster that knowledge.

This meta-analysis may finally clarify which patients are most likely to respond to hormonal therapy.

Dr Kathy Miller highlights potential practice-changing studies that she is looking forward to at SABCS 2017.